ArticleBMC nephrology2025
NR3C1 variants and glucocorticoid response in childhood nephrotic syndrome in North India.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundNephrotic syndrome (NS) is a common kidney disorder in children, characterized by significant proteinuria, hypoalbuminemia, and peripheral edema. While glucocorticoids (GCs) are the first-line treatment for pediatric nephrotic syndrome (NS), a subset of patients exhibit steroid resistance, leading to poor prognosis and a higher risk of long-term kidney damage. The glucocorticoid receptor gene (NR3C1) plays a pivotal role in mediating the effects of GCs, and its polymorphisms have been implicated in variable GC responses.
methodsThis study investigates the association between NR3C1 single nucleotide polymorphisms (SNPs) (rs6877893 and rs10482634) in 50 patients with steroid-sensitive nephrotic syndrome (SSNS) and 50 steroid-resistant nephrotic syndrome (SRNS) individuals by Kompetitive Allele Specific Polymerase Chain Reaction (KASP) assay and altered GC receptors (GRα and GRβ) expression by Real-Time PCR (RT-PCR). Adverse effect of steroid therapy was also assessed.
resultsGenotyping revealed a significant association between GG genotype of SNP rs10482634 and steroid resistance, suggesting that it may contribute to the heterogeneity in GC response in this population. There is also a positive association of AA genotype of rs10482634 with short stature and AG genotype of rs10482634 with cushingoid habitus, as a side effect of steroid therapy. We have also found an enhanced expression of GRα in SSNS population. No significant association was found between the SNP rs6877893 and the response to steroid treatment in the study cohort. Our study revealed higher rates of drug-related complications in patients receiving larger cumulative doses of steroids.
conclusionThese findings highlight the importance of genetic screening of NR3C1 SNPs in predicting steroid responsiveness and tailoring personalized therapeutic strategies in pediatric NS. CLINICAL TRIAL NUMBER: not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.